Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 76, Issue 1, 1997, Pages

  Herting, Egbert ^a,b   Sun, Bo ^b   Jarstrand, Connie ^c   Curstedt, Tore ^d   Robertson, Bengt ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

Bacterial growth; Group B streptococci; Lung function; Rabbits; Surfactant

Indexed keywords

LUNG SURFACTANT; LUNG SURFACTANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL GROWTH; BODY PLETHYSMOGRAPHY; DOSE RESPONSE; LUNG COMPLIANCE; LUNG HOMOGENATE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIA; SURVIVAL TIME; TRACHEOTOMY;

EID: 0031394712     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.76.1.F3     Document Type: Article

References (34)

1. Committee on Infectious Diseases and Committee on the Fetus and Newborn. Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. Pediatrics 1992;90:775-8.
2. Weissman LE, Stoll BJ, Cruess DF, Hall RT, Merenstein GB, Hemming VG, et al. Early onset group B-streptococcal sepsis: a current assessment. J Pediatr 1992;121:428-33.
3. Ablow R, Driscoll S, Effmann E, Gross I, Jolles CJ, Uauy R, et al. A comparison of early onset group B streptococcal neonatal infection and the respiratory distress syndrome. N Engl J Med 1976;294:65-70.
4. Sherman MP, D'Ambola J, Aeberhard E, Barrett CT. Surfactant therapy of newborn rabbits impairs lung macrophage bactericidal activity. J Appl Physiol 1988;65:137-45.
5. Speer CP, Götze B, Curstedt T, Robertson B. Phagocytic function and TNF secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr Res 1991;30:69-74.
6. Jarstrand C, Berggren P, Curstedt T, Johansson A, Robertson B, Wienic A. Influence of lung surfactant phospholipids on neutrophilic granulocytes and blood monocytes. Prog Respir Res 1984;18:44-50.
7. Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B. Experimental neonatal Group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits. Pediatr Res 1994;36:784-91.
8. Håkansson S, Berholm AM, Holm SE, Wagner B, Wagner M. Properties of high and low density subpopulations of group B streptococci: enhanced virulence of the low density variant. Microbiol Pathol 1988;5:345-55.
9. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988;82:683-91.
10. Sun B, Kobayashi T, Curstedt T, Grossmann G, Robertson B. Application of a new ventilator-multi-plethysmograph system for testing efficacy of surfactant replacement in newborn rabbits. Eur Respir J 1991;4:364-70.
11. Rider ED, Jobe AH, Ikegami M, Sun B. Different ventilation strategies alter surfactant responses in preterm rabbits. J Appl Physiol 1992;73:2089-96.
12. Sherman MP, Campbell LA, Merritt TA, Long WA, Gunkel JH, Curstedt T, et al. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J Pediatr 1994;125:939-47.
13. Hall SL, Sherman MP. Intrapulmonary bacterial clearance of type III group B streptococcus is reduced in preterm compared with term rabbits and occurs independent of antibody. Am Rev Respir Dis 1992;145:1172-7.
14. Payne NR, Burke BA, Day DL, Christenson PC, Thompson TR, Ferrieri P. Correlation of clinical and pathologic findings in early onset neonatal Group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J 1988;7:836-47.
15. Katzenstein AL, Davis C, Braude A. Pulmonary changes in neonatal sepsis due to Group B β-hemolytic streptococcus: relation to hyaline membrane disease. J Infect Dis 1976;4:430-5.
16. Walther FJ. Surfactant therapy for neonatal lung disorders other than respiratory distress syndrome. In: Robertson B, Taeusch HW, eds. Surfactant therapy for lung disease. New York: Marcel Dekker, 1995: 461-89.
17. Sun B, Herting E, Curstedt T, Robertson B. Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration. J Appl Physiol 1994;77:1961-71.
18. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990;29:8424-9.
19. Van Iwaarden JF. Surfactant and the pulmonary defense system. In: Robertson B, van Golde LMG, Batenburg JJ, eds. Pulmonary Surfactant. From Molecular Biology to Clinical Practice. Amsterdam: Elsevier, 1993: 215-25.
20. Herting E, Jarstrand C, Rasool O, Curstedt T, Hakansson S, Robertson B. Effect of surfactant on nitroblue tetrazolium (NBT) reduction of polymorphonuclear leucocytes stimulated with type Ia group B streptococci. Acta Paediatr 1995;84:922-6.
21. Herting E, Jarstrand C, Curstedt T, Sun B, Calkovska A, Robertson B. Neonatal experimental group B streptococcal pneumonia: effects of gestational age, infectious dose and surfactant treatment on bacterial proliferation and inflammatory response. Applied Cardiopulmonary Pathophysiology 1995;5 (suppl 3):58-9.
22. Strayer DS, Herting E, Sun B, Robertson B. Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Am J Respir Crit Care Med 1996;153:1116-22.
23. Herting E, Strayer DS, Sun B, Robertson B. Influence of a monoclonal anti-SP-A antibody (R 5) on bacterial growth in term rabbits with experimental neonatal Group B streptococcal pneumonia. Biol Neonate 1996;69:217.
24. Auten RL, Nouer RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87:101-7.
25. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993;92:135-9.
26. Herting E, Speer CP, Sun B, Jarstrand C, Curstedt T, Robertson B. Einfluß von Surfactant auf pulmonales Entzündungsgeschehen und Elastase-Freisetzung bei experimenteller neonataler B-Streptokokkenpneumonie. Monatschr Kinderheilkd 1996;144:1319-25.
27. Speer CP, Reuss D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993;91:794-9.
28. Pison U, Tam EK, Caughey GH, Hawgood S. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta 1989;92:251-7.
29. Walmrath D, Günther A, Ghofrani HA, Schermuly R, Schneider T, Grimminger F, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996;154:57-62.
30. McCormack FX, Mason RJ. Surfactant therapy for adult respiratory distress syndrome. In: Robertson B, Taeusch HW, eds. Surfactant therapy for lung disease. New York: Marcel Dekker, 1995: 573-600.
31. Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX. Surfactant treatment in experimental Escherichia coli pneumonia. Acta Anaesthesiol Scand 1996;40:1152-9.
32. Eijking EP, van Daal GJ, Tenbrinck R, Luijendijk A, Sluiters JF, Hannappel E, et al. Effect of surfactant replacement on pneumocystis carinii pneumonia in rats. Intensive Care Med 1991;17:475-8.
33. Van Daal GJ, So KL, Gommers D, Eijking EP, Fiévez RB, Sprenger MJ, et al. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 1991;72:589-95.
34. Van Daal GJ, Bos JAH, Eijking EP, Gommers D, Hannappel E, Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 1992;145:859-63.